Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.4000
-0.0250 (-5.88%)
Mar 31, 2025, 2:27 PM EDT - Market open
Bolt Biotherapeutics Employees
Bolt Biotherapeutics had 100 employees as of December 31, 2023. The number of employees increased by 6 or 6.38% compared to the previous year.
Employees
100
Change (1Y)
6
Growth (1Y)
6.38%
Revenue / Employee
$76,900
Profits / Employee
-$631,180
Market Cap
15.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 100 | 6 | 6.38% |
| Dec 31, 2022 | 94 | 3 | 3.30% |
| Dec 31, 2021 | 91 | 26 | 40.00% |
| Dec 31, 2020 | 65 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BOLT News
- 5 days ago - Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - GlobeNewsWire
- 6 days ago - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Bolt Biotherapeutics to Participate in Upcoming March Conferences - GlobeNewsWire
- 6 weeks ago - Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. - GlobeNewsWire
- 5 months ago - Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm - Accesswire
- 7 months ago - Bolt Biotherapeutics Announces Changes to its Board of Directors - GlobeNewsWire
- 7 months ago - Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm - Accesswire